Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: A diagnostic aid

Nazarian, Rosalynn M.; Mandal, Rajni; Kagan, Anna; Kay, Jonathan; Duncan, Lyn M.

doi:10.1016/j.jaad.2010.05.034

Cited by 13 publications

(7 citation statements)

References 25 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Skin histology demonstrated disorganized collagen bundles and an increase in the number of densely nucleated cells in the dermis (Figure 2c). The quantitative increase in dermal cellularity was on the same order as the non-nephrectomized mice treated with gadolinium-based contrast agents (Figure 1c), and this is similar to what has been described in patients with NSF (Nazarian et al, 2011). Gadolinium content in the contrast agentetreated skin was 87 AE 5 (mean AE standard error) mg/g tissue as measured in flash-frozen skin by inductively coupled plasma mass spectroscopy.…”

Section: Resultssupporting

confidence: 82%

Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2

Drel

Tan

et al. 2019

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Gadolinium-based contrast agents are implicated in several pathologic abnormalities (long-term retention in vital organs such as the skin and the brain) and are the cause of a sometimes fatal condition in patients, nephrogenic systemic fibrosis. Bone marrowederived fibrocytes and the monocyte chemoattractant protein-1 inflammatory pathway have been implicated as mediators of the adverse effects induced by gadolinium-based contrast agents. Mechanistic studies are scant; therefore, a mouse model of nephrogenic systemic fibrosis was established. Dermal cellularity was increased in contrast-treated green fluorescent protein (GFP) chimeric mice. GFP in the skin and fibrosis were increased in the contrast-treated chimeric animals. Monocyte chemoattractant protein-1 and CC chemokine receptor 2 were increased in the tissues from contrast-treated mice. CC chemokine receptor 2edeficient recipients of GFP-expressing marrow had an abrogation of gadolinium-induced pathology and displayed less GFP-positive cells in the skin. Wild-type animals that received CC chemokine receptor 2edeficient bone marrow had a complete abrogation of dermal pathology. That GFP levels and expression increase in the skin, in tandem with a fibrocyte marker, supports the blood-borne circulating fibrocyte hypothesis of the disease. As of now, fibrocyte trafficking has yet to be demonstrated. Importantly, our data demonstrate that the monocyte chemoattractant protein-1/C-C chemokine receptor 2 axis plays a critical role in the pathogenesis of nephrogenic systemic fibrosis.

show abstract

Section: Resultssupporting

confidence: 82%

Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2

Drel

Tan

et al. 2019

Journal of Investigative Dermatology

View full text Add to dashboard Cite

show abstract

“…Additionally, in the current study, the increased cellularity was seen in both the superficial and deep dermis; this was not seen in our previous experiments and may be related to the decreased duration of gadodiamide injections, over 5 days rather than 20 days, which likely resulted in increased lesion severity [15,16,22]. Increased dermal cellularity has been demonstrated in clinical NSF patients [23]. Additionally, histology at 16 weeks also demonstrated qualitatively increased fibrosis and plaque-like changes, both hallmarks of clinical NSF [24].…”

Section: Discussioncontrasting

confidence: 53%

Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model

Hope¹,

LeBoit²,

High³

et al. 2013

Magnetic Resonance Imaging

View full text Add to dashboard Cite

“…Omniscan treatment led to a great increase in myeloid cells in the skin concomitant with extracellular matrix deposition, α-smooth muscle actin expression, and fibrocyte cellular markers. The increase in dermal cellularity was identical to that seen in patients suffering from ‘nephrogenic’ systemic fibrosis [17]. Moreover, gadolinium-based contrast agent treatment increased the quantity of reactive oxygen species in the skin parallel with an increase of NAPDH oxidase type 4 (Nox4).…”

Section: Who’s Afraid Of ‘Nephrogenic’ Systemic Fibrosis?mentioning

confidence: 70%

Gadolinium-based contrast agents

Leyba

Wagner

2019

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

Purpose of review The hegemony of gadolinium-based contrast agent-induced adverse events stretches beyond those who have renal impairment. ‘Nephrogenic’ systemic fibrosis is a misnomer: gadolinium-based contrast agents are the known trigger for the disease; kidney impairment is a risk factor. Impaired (true) glomerular filtration may be one catalyst for gadolinium-based contrast agent-induced adverse events, but it is increasingly evident that the same cluster of symptoms occurs in patients with normal renal function. Recent findings It has been known for nearly 30 years that gadolinium-based contrast agents distribute and are cleared according to a three compartment model. Single doses of gadolinium-based contrast agents can trigger ‘nephrogenic’ systemic fibrosis in nondialysis dependent patients. Manifestations have occurred years after exposure. Renal insufficiency alone is not an adequate explanation for nephrogenic systemic fibrosis, and the continuum of its symptoms with the adverse events reported by patients with normal renal function clearly indicate that the physiologic reactions are largely undefined. Summary Gadolinium-based contrast agents should be used with extreme caution.

show abstract

Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: A diagnostic aid

Cited by 13 publications

References 25 publications

Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2

Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2

Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model

Gadolinium-based contrast agents

Contact Info

Product

Resources

About